Business
fromFast Company
2 days agoEli Lilly's obesity and diabetes treatments fuel growth and spark bidding war
Eli Lilly's GLP-1 drugs Mounjaro and Zepbound generated over $10 billion in Q3, driving record revenue, profit, and industry acquisition interest.